Research Axis 3: Development of new biomarkers and innovative personalized therapies

Development of diagnostic tools and Development of therapeutic tools. This research axis aims to identify biomarkers and develop specific inhibitors targeting the bacteria-cell interaction.
  • Development of diagnostic tools.
    • Molecular detection of AIEC bacteria
    • Search for biomarkers to identify AIEC-colonized CD patients
    • Predictive diagnosis of post-operative recurrence in CD patients
    • Colibactin-producing E. coli as a pronostic marker in CRC
  • Development of therapeutic tools
    • Impact of physical activity on microbiota composition in chronic diseases
    • Inhibition of type 1 pili-CEACAM6 interaction
    • Antagonist effects of Probiotics against pathogenic E. coli
    • Eradication of AIEC using antibiotherapy strategies
    • Inhibition of the genotoxic action of the pks genomic island
    • Curcumin as a complementary therapeutic strategy: impact on the intestinal microbiota